Perspective Therapeutics, Inc. (NYSE:CATX) Receives $19.80 Consensus PT from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been given an average recommendation of “Buy” by the seven research firms that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $19.80.

A number of brokerages have weighed in on CATX. Bank of America started coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Oppenheimer dropped their target price on Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, Royal Bank of Canada reduced their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research report on Friday, August 16th.

Perspective Therapeutics Stock Down 1.8 %

Shares of NYSE:CATX opened at $13.23 on Monday. The stock has a 50-day simple moving average of $13.81. Perspective Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. Sell-side analysts forecast that Perspective Therapeutics will post -0.86 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ZWJ Investment Counsel Inc. bought a new position in shares of Perspective Therapeutics during the 1st quarter valued at approximately $26,000. Simplicity Wealth LLC bought a new position in shares of Perspective Therapeutics in the first quarter worth approximately $40,000. Bleakley Financial Group LLC purchased a new stake in shares of Perspective Therapeutics in the first quarter worth $40,000. Victory Capital Management Inc. bought a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at $117,000. Finally, Point72 DIFC Ltd purchased a new position in shares of Perspective Therapeutics during the 2nd quarter valued at $118,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.